Pharmacovigilance in Japan & China - An Interview with Edward Stewart Geary
Pharma IQ: Can you outline the requirements for expedited and periodic reporting in Japan?
Stewart Geary: There are requirements for expedited reporting of individual case safety reports (ICSRs) both during clinical development and post-marketing as well as requirements for expedition of research reports and foreign action (measures taken overseas for safety) reports. All ICSR reporting in Japan is in an E2B-style electronic format. For periodic repo...
To continue reading this story get free access
Please note: That all fields marked with an asterisk (*) are required.